Literature DB >> 33026575

The role of caspase-8 in the tumor microenvironment of ovarian cancer.

Izabela Kostova1, Ranadip Mandal1, Sven Becker1, Klaus Strebhardt2,3,4.   

Abstract

Caspase-8 is an aspartate-specific cysteine protease, which is best known for its apoptotic functions. Caspase-8 is placed at central nodes of multiple signal pathways, regulating not only the cell cycle but also the invasive and metastatic cell behavior, the immune cell homeostasis and cytokine production, which are the two major components of the tumor microenvironment (TME). Ovarian cancer often has dysregulated caspase-8 expression, leading to imbalance between its apoptotic and non-apoptotic functions within the tumor and the surrounding milieu. The downregulation of caspase-8 in ovarian cancer seems to be linked to high aggressiveness with chronic inflammation, immunoediting, and immune resistance. Caspase-8 plays therefore an essential role not only in the primary tumor cells but also in the TME by regulating the immune response, B and T lymphocyte activation, and macrophage differentiation and polarization. The switch between M1 and M2 macrophages is possibly associated with changes in the caspase-8 expression. In this review, we are discussing the non-apoptotic functions of caspase-8, highlighting this protein as a modulator of the immune response and the cytokine composition in the TME. Considering the low survival rate among ovarian cancer patients, it is urgently necessary to develop new therapeutic strategies to optimize the response to the standard treatment. The TME is highly heterogenous and provides a variety of opportunities for new drug targets. Given the variety of roles of caspase-8 in the TME, we should focus on this protein in the development of new therapeutic strategies against the TME of ovarian cancer.

Entities:  

Keywords:  Caspase-8; Macrophages; Non-apoptotic functions; Ovarian cancer treatment; TAMs; Tumor microenvironment

Mesh:

Substances:

Year:  2020        PMID: 33026575      PMCID: PMC7897206          DOI: 10.1007/s10555-020-09935-1

Source DB:  PubMed          Journal:  Cancer Metastasis Rev        ISSN: 0167-7659            Impact factor:   9.264


  77 in total

1.  Downregulation of Caspase 8 in a group of Iranian breast cancer patients - A pilot study.

Authors:  Masoumeh Aghababazadeh; Najmeh Dorraki; Fahimeh Afzal Javan; Asieh Sadat Fattahi; Masoumeh Gharib; Alireza Pasdar
Journal:  J Egypt Natl Canc Inst       Date:  2017-12-07

2.  Cancer statistics, 2020.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2020-01-08       Impact factor: 508.702

3.  Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome.

Authors:  Richard W Tothill; Anna V Tinker; Joshy George; Robert Brown; Stephen B Fox; Stephen Lade; Daryl S Johnson; Melanie K Trivett; Dariush Etemadmoghadam; Bianca Locandro; Nadia Traficante; Sian Fereday; Jillian A Hung; Yoke-Eng Chiew; Izhak Haviv; Dorota Gertig; Anna DeFazio; David D L Bowtell
Journal:  Clin Cancer Res       Date:  2008-08-15       Impact factor: 12.531

Review 4.  Non-apoptotic functions of caspase-8.

Authors:  Jonathan Maelfait; Rudi Beyaert
Journal:  Biochem Pharmacol       Date:  2008-08-06       Impact factor: 5.858

Review 5.  Targeting the tumour microenvironment in ovarian cancer.

Authors:  Jean M Hansen; Robert L Coleman; Anil K Sood
Journal:  Eur J Cancer       Date:  2016-02-03       Impact factor: 9.162

6.  Ovarian Cancer: A Heterogeneous Disease.

Authors:  Myriam Kossaï; Alexandra Leary; Jean-Yves Scoazec; Catherine Genestie
Journal:  Pathobiology       Date:  2017-10-12       Impact factor: 4.342

7.  A dual role for Caspase8 and NF-κB interactions in regulating apoptosis and necroptosis of ovarian cancer, with correlation to patient survival.

Authors:  L Hernandez; M K Kim; A M Noonan; E Sagher; H Kohlhammer; G Wright; L T Lyle; P S Steeg; M Anver; D D Bowtell; C M Annunziata
Journal:  Cell Death Discov       Date:  2015-12-14

Review 8.  Chemoresistance and targeted therapies in ovarian and endometrial cancers.

Authors:  Kevin Brasseur; Nicolas Gévry; Eric Asselin
Journal:  Oncotarget       Date:  2017-01-17

Review 9.  Role of tumor microenvironment in the pathobiology of ovarian cancer: Insights and therapeutic opportunities.

Authors:  Alia Ghoneum; Hesham Afify; Ziyan Salih; Michael Kelly; Neveen Said
Journal:  Cancer Med       Date:  2018-08-21       Impact factor: 4.452

Review 10.  Ovarian cancer: Current status and strategies for improving therapeutic outcomes.

Authors:  Ashwin Chandra; Cima Pius; Madiha Nabeel; Maya Nair; Jamboor K Vishwanatha; Sarfraz Ahmad; Riyaz Basha
Journal:  Cancer Med       Date:  2019-09-27       Impact factor: 4.452

View more
  6 in total

1.  Significance of CD47 and Its Association With Tumor Immune Microenvironment Heterogeneity in Ovarian Cancer.

Authors:  Lan Yu; Yi Ding; Ting Wan; Ting Deng; He Huang; Jihong Liu
Journal:  Front Immunol       Date:  2021-12-13       Impact factor: 7.561

2.  Caspase-8 Deficient Osteoblastic Cells Display Alterations in Non-Apoptotic Pathways.

Authors:  Barbora Vesela; Michael Killinger; Kamila Rihova; Petr Benes; Eva Svandová; Adela Kratochvilová; Filip Trcka; Karel Kleparnik; Eva Matalova
Journal:  Front Cell Dev Biol       Date:  2022-03-15

3.  TRIM21 deficiency promotes cell proliferation and tumorigenesis via regulating p21 expression in ovarian cancer.

Authors:  Jieyun Sun; Xintian Chen; Xueying Ji; Sen Meng; Wenwen Wang; Pengfei Wang; Jin Bai; Zhongwei Li; Youguo Chen
Journal:  Bioengineered       Date:  2022-03       Impact factor: 3.269

4.  Fisetin-induced cell death in human ovarian cancer cell lines via zbp1-mediated necroptosis.

Authors:  Yaxian Liu; Hongwen Cao; Yanhui Zhao; Lijuan Shan; Shuhai Lan
Journal:  J Ovarian Res       Date:  2022-05-10       Impact factor: 5.506

5.  The Relationship of Pyroptosis-Related Genes, Patient Outcomes, and Tumor-Infiltrating Cells in Bladder Urothelial Carcinoma (BLCA).

Authors:  Ruiyan Xie; Ming Xie; Litong Zhu; Joanne W Y Chiu; Wayne Lam; Desmond Y H Yap
Journal:  Front Pharmacol       Date:  2022-07-19       Impact factor: 5.988

Review 6.  Targeting CDK9 for Anti-Cancer Therapeutics.

Authors:  Ranadip Mandal; Sven Becker; Klaus Strebhardt
Journal:  Cancers (Basel)       Date:  2021-05-01       Impact factor: 6.639

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.